Physician profile
Bryan D Tate
NPI 1407177348
$1,017.20
in general payments reported to CMS, 2019-2025
18 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $270 · 2023: $311 · 2024: $156 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $159.56 | 2021-2025 | Repatha, Otezla, Otezla |
| Medtronic, INC. | $131.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $123.93 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Renalytix Ai, INC. | $108.88 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Novo Nordisk INC | $75.93 | 2023-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $69.75 | 2021-2023 | Trelegy Ellipta |
| Abbvie INC. | $58.38 | 2022-2024 | |
| Tolmar, INC. | $48.14 | 2025 | Jatenzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.75 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.69 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.82 | 2021 | |
| Axsome Therapeutics, INC. | $24.51 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.07 | 2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $18.86 | 2023 | |
| Genentech USA, INC. | $17.64 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.66 | 2021 | |
| Ascensia Diabetes Care US INC. | $16.38 | 2021 | |
| Abbott Laboratories | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.